Search results for "Menopausa"

showing 10 items of 119 documents

Early Denosumab for the prevention of osteoporotic fractures in breast cancer women undergoing aromatase inhibitors: A case-control retrospective stu…

2021

BACKGROUND: Aromatase inhibitors (AIs) might have a detrimental impact on bone health in breast cancer (BC) women. Denosumab has been shown to reduce the risk of fractures, but the appropriate time for starting is yet to be clearly defined. OBJECTIVE: To evaluate the effects of early treatment with Denosumab (⩽ 12 months after starting AIs) compared to a delayed treatment in BC women. METHODS: In this retrospective case-control study, we included medical records of BC post-menopausal women, treated with AIs therapy; they were divided as: study group (starting Denosumab ⩽ 12 months after AIs) and control group (> 12 months). At the baseline (T0) and at 18 months (T1), we evaluated the lum…

Osteoporosisrisk of fracture0302 clinical medicineRetrospective StudieBone DensityOrthopedics and Sports Medicine030212 general & internal medicineAromataseOsteoporosis PostmenopausalbiologyBone Density Conservation AgentsAromatase InhibitorsSettore MED/34 - Medicina Fisica E RiabilitativaMedical recordRehabilitationMiddle Agedmedicine.anatomical_structureDenosumab030220 oncology & carcinogenesisOsteoporosis risk of fractures breast cancer denosumab bone healthFemaleDenosumabCase-Control StudieBreast NeoplasmHumanmedicine.drugmedicine.medical_specialtyBone Density Conservation AgentPhysical Therapy Sports Therapy and RehabilitationBreast NeoplasmsBone health03 medical and health sciencesbreast cancerBreast cancerInternal medicinemedicineAromatase InhibitorHumansbone healthFemoral neckAgedRetrospective Studiesrisk of fracturesbusiness.industryOsteoporosiRetrospective cohort studymedicine.diseaseCase-Control Studiesbiology.proteinbusinessOsteoporotic Fractures
researchProduct

Dental considerations in pregnancy and menopause

2011

The present study offers a literature review of the main oral complications observed in women during pregnancy and menopause, and describes the different dental management protocols used during these periods and during lactation, according to the scientific literature. To this effect, a PubMed-Medline search was made, using the following key word combinations: “pregnant and dentistry”, “lactation and dentistry”, “postmenopausal and dentistry”, “menopausal and dentistry” and “oral bisphosphonates and dentistry”. The search was limited to reviews, metaanalyses and clinical guides in dental journals published over the last 10 years in English and Spanish. A total of 38 publications were evalua…

PeriodontitisPregnancyPostmenopausal womenbusiness.industryDental proceduresOsteoporosisDentistryOdontologíaBurning mouth syndrome:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseCiencias de la saludMenopausestomatognathic diseasesGingivitisUNESCO::CIENCIAS MÉDICASMedicinemedicine.symptombusinessGeneral DentistryJournal of Clinical and Experimental Dentistry
researchProduct

Effect of hormone replacement therapy (HRT) on periodontal status of postmenopausal women.

2011

Summary Background The risks/benefits balance of hormone replacement therapy (HRT) is controversial. The aim of this study was to assess the periodontal status of a postmenopausal women group receiving HRT and to determine the effects of HRT on clinical measures of periodontal disease. Material/Methods Ninety-one postmenopausal women, 52 taking HRT (HRT+) and 39 not taking HRT (HRT−), completed the study. Clinical parameters measured included visible supragingival plaque, probing pocket depth (PD) and clinical attachment level (CAL). Gingival status was recorded as gingival bleeding on probing (BOP). Previous oral contraceptive use and current and past smoking status were also assessed. Res…

Periodontiummedicine.medical_specialtygenetic structuresPeriodontal diseaseSettore MED/28 - Malattie OdontostomatologicheInternal medicineMedicineHumansEstrogen replacement therapyperiodontitisGynecologyPostmenopausal womenbusiness.industryEstrogen Replacement TherapyGeneral MedicineMiddle Agedeye diseaseshormone replacement therapypostmenopausefemaleTransgender hormone therapyhormone replacement therapy (HRT) postmenopause chronic periodontitis gingivitis femalesense organsPublic HealthbusinessgingivitisMedical science monitor : international medical journal of experimental and clinical research
researchProduct

Management of depressive symptoms in peri- and postmenopausal women: EMAS position statement.

2019

Introduction: Globally, the total number of people with depression exceeds 300 million, and the incidence rate is 70 % greater in women. The perimenopause is considered to be a time of increased risk for the development of depressive symptoms and major depressive episodes. Aim: The aim of this position statement is to provide a comprehensive model of care for the management of depressive symptoms in perimenopausal and early menopausal women, including diagnosis, treatment and follow-up. The model integrates the care provided by all those involved in the management of mild or moderate depression in midlife women. Materials and methods: Literature review and consensus of expert opinion. Summa…

Position statementAdultComplementary Therapiesmedicine.medical_specialtyPeriMenopausal Hormone TherapyGeneral Biochemistry Genetics and Molecular BiologyEMAS03 medical and health sciences0302 clinical medicinemedicineHumans030212 general & internal medicineModel of CarePsychiatryEarly MenopauseLife StyleDepressive symptomsDepression (differential diagnoses)Societies MedicalAgedDepressive Disorder Major030219 obstetrics & reproductive medicinePostmenopausal womenVasomotorbusiness.industryDepressionObstetrics and GynecologyMenopausal TransitionMiddle AgedAntidepressive AgentsHormones3. Good healthPerimenopauseEuropePostmenopauseTreatment OutcomePractice Guidelines as TopicFemaleMenopausal hormone therapyMenopausebusinessPsychosocialMaturitas
researchProduct

Spanish Menopause Society position statement: Use of denosumab in postmenopausal women

2014

Denosumab is a new drug developed for the treatment of osteoporosis. Moreover, increasing evidences link denosumab with benefits in cancer, an area of interest for those in charge of the postmenopausal health. Denosumab has shown efficacy in the control of bone loss associated with hypogonadic states created by chemotherapy in breast and other cancers. Moreover, some studies reveal efficacy in reducing the progression of metastases. A panel of experts from the Spanish Menopause Society has met to develop usage recommendations based on the best available evidence.

Position statementOncologymedicine.medical_specialtyInjections SubcutaneousOsteoporosisBone NeoplasmsBreast NeoplasmsGeneral Biochemistry Genetics and Molecular BiologyFractures BoneBreast cancerBone DensityInternal medicinemedicineHumansOsteoporosis PostmenopausalPostmenopausal womenBone Density Conservation Agentsbusiness.industryObstetrics and GynecologyCancerArea of interestmedicine.diseasePostmenopauseMenopauseDenosumabDisease ProgressionPhysical therapyFemaleBone RemodelingDenosumabSafetybusinessmedicine.drugMaturitas
researchProduct

Association between tibial subchondral bone structure from plain radiographs and cartilage composition from quantitative MRI in postmenopausal women …

2016

Postmenopausal womenbusiness.industryCartilageBiomedical EngineeringDentistryOsteoarthritismedicine.diseasemedicine.anatomical_structureRheumatologySubchondral bonemedicineOrthopedics and Sports MedicinePlain radiographsbusinessOsteoarthritis and Cartilage
researchProduct

On the use and abuse of register studies: The case of menopausal hormone therapy

2019

Register (sociolinguistics)medicine.medical_specialtybusiness.industryInternal medicineMEDLINEObstetrics and GynecologyMedicineMenopausal hormone therapy610 Medicine & healthbusinessGeneral Biochemistry Genetics and Molecular Biology
researchProduct

Comparison of soft tissue body composition in postmenopausal women with or without hormone replacement therapy considering the influence of reproduct…

2001

To examine long-term effects of at least 5 years' conventional hormone replacement therapy (HRT), reproductive history and lifestyle on fat mass and muscle mass in postmenopausal women.A cross-sectional retrospective approach was used, including 64 healthy women (56-69 years, mean age 63.4 years). Hormone users were compared with age-matched non-users with respect to (a) type of HRT used (oestrogen vs oestrogen plus gestagen vs no hormones), (b) categories of oestrogens used (oestradiol-based oestrogens vs conjugated equine oestrogens vs no oestrogens) and (c) categories of gestagens used (testosterone derivatives vs progesterone derivatives vs no gestagens). Data on hormone use, reproducti…

Research designAgingmedicine.medical_specialtyPhysiologyEpidemiologyHormone Replacement TherapyPhysiologySurveys and QuestionnairesGeneticsElectric ImpedanceMedicineHumansLife StyleTestosteroneAgedRetrospective StudiesGynecologyAnalysis of VariancePostmenopausal womenAnthropometrybusiness.industryPublic Health Environmental and Occupational HealthSoft tissueMiddle AgedPhysical activity levelPostmenopauseCross-Sectional StudiesTransgender hormone therapyCase-Control StudiesMenarcheBody CompositionFemalebusinessHormoneAnnals of human biology
researchProduct

[Protein intake in community-dwelling postmenopausal women and its relationship with sarcopenia].

2021

Objectives: the general aging of the population is related to the increase in the prevalence of sarcopenic disease; especially among older women, this pathology is closely related to nutrition and specifically to protein consumption in older adults. The aim of our study was to evaluate the possible relationship between a low protein intake and a higher prevalence of sarcopenic disease, a worse dietary pattern, and lower physical performance in postmenopausal women living in the community. Material and methods: the study was carried out in a total of 164 independent women over 65 years of age, recruited from a municipal social center in Valencia (Benimaclet). The presence of sarcopenic patho…

SarcopeniaLow proteinPopulationMedicine (miscellaneous)DiseaseEnvironmental healthPrevalenceMedicineHumansSarcopenic obesityeducationAgedAged 80 and overeducation.field_of_studyNutrition and DieteticsPostmenopausal womenbusiness.industryMiddle AgedProtein intakeMicronutrientmedicine.diseasePostmenopauseSarcopeniaFemaleDietary ProteinsIndependent LivingbusinessEnergy IntakeNutricion hospitalaria
researchProduct

Are the serum levels of sCD40L modified by raloxifene in postmenopausal women?

2008

Selective Estrogen Receptor Modulatorsmedicine.medical_specialtyPostmenopausal womenbusiness.industryObstetricsCD40 LigandObstetrics and GynecologyMiddle AgedReproductive MedicineRaloxifene HydrochloridemedicineHumansRaloxifeneFemalebusinessOsteoporosis Postmenopausalmedicine.drugEuropean journal of obstetrics, gynecology, and reproductive biology
researchProduct